Dietary Soy Isoflavones In Chronic Pancreatitis
Chronic Pancreatitis
About this trial
This is an interventional treatment trial for Chronic Pancreatitis
Eligibility Criteria
Inclusion Criteria:
Diagnosis of chronic pancreatitis by fulfilling one of the following clinical scenarios:
- Presence of pancreatic calcifications
- Suggestive for chronic pancreatitis - consistent EUS criteria or at least 3 abnormal side branches on pancreatic duct imaging
- Indeterminate EUS findings for chronic pancreatitis with evidence of exocrine pancreatic insufficiency (EPI)
- Age ≥18 years
Exclusion Criteria:
- Inability to provide written consent
- Inability to comply with the study protocol
- Soy allergy
- Pancreatic cancer
- History of prior pancreatic surgery (this does not include endoscopic therapies)
- Comorbid diseases characterized by a chronic inflammatory state, including, but not limited to rheumatologic diseases, chronic kidney disease, extra-pancreatic malignancy
- Pregnancy
Sites / Locations
- Philip Hart
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Dose Escalation (DE) Phase
Maximum Tolerated Dose (MTD) Phase
Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in >33% of the participants or the daily target dose of 4 slices of bread [132 mg soy isoflavone] is reached.
After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.